Executive team

Stijn Van Rompay


Stijn co-founded and was the CEO of Alter Pharma, a high-growth pharmaceutical company focused on the development of complex generics and pharmacy-related product sales. He was also co-CEO of Uteron Pharma, a company focused on innovative female healthcare products.

Prior to these positions, Stijn was CFO and later, CEO of Docpharma (formerly quoted on Euronext Brussels) a generics and medical-device company. Under his leadership, the companies recorded strong growth and value creation. He also holds several non-executive director positions in the biotech sector, and acts as an advisor to venture capital investors. Stijn holds a Master’s degree in Applied Economics from the University of Antwerp.

Thomas Jacobsen


Thomas co-founded Alter Pharma, a high-growth pharmaceutical company focused on the development of complex generics and pharmacy-related product sales, where he managed the generic division. Before joining Alter Pharma, he worked at Docpharma, a generics and medical-device company. Thomas started his career in the Scandinavian-based generics company Alternova, where he was responsible for licensing, registering and launching the company’s products. Thomas holds a Master’s degree in Pharmacy from the University of Copenhagen, as well as a Business degree from Copenhagen Business School.

Astrid Heiremans


Ms. Astrid Heiremans has more than 15 years’ experience in various industries (production, consumer retail, business services) focusing both on compliance and on defining and implementing financial and operational strategies. Before joining the Issuer as CFO on 15 June 2020, Astrid, among other things, had a 10 year career at Deloitte serving as a Senior Audit Manager. She currently also serves as an independent non-executive director and chairperson of the audit committee at the House of HR NV.

Astrid holds a Master of Commercial Engineer from the University of Leuven (KULeuven).

Ed Maloney


Ed’s previous roles include President of Milla Pharmaceuticals US, a subsidiary of Alter Pharma. Ed was the Business Development Vice President at Paddock Laboratories, responsible for in-licensing, out-licensing and joint venture deals. Before becoming the Business Development VP, Ed was Vice President of Operations at Paddock Laboratories, a manufacturer of solid, liquid and semi-solid products. Previously, Ed served as a board member of the Generic Pharmaceutical Association (GPhA-US). He joined Hyloris as Chief Business Development Officer in 2013. Ed graduated from the University of Minnesota with a BSB in Business Administration.

Koenraad Van der Elst


Koenraad served as General Counsel at Metris (currently Nikon Metrology), and acted as Secretary General & General Counsel of PUNCH INTERNATIONAL, a Belgian company listed on Euronext Brussels. He was also General Counsel & Secretary to the Board of PUNCH GRAPHIX plc, a company listed on the London Stock Exchange (AIM), and President of the Supervisory Board of PUNCH TECHNIX, a company listed on Euronext Amsterdam. Between 1995 and 2002, Koenraad was the Director of Legal Documentation at the Investment Banking Department (corporate finance & capital markets) of Generale Bank/Fortis Bank and was involved in most capital market transactions in Belgium (take-over bids, exchange offers, initial public offerings, etc.), as well as in a large number of corporate finance deals (M&A, advisory, fairness opinions, mergers, restructurings, etc.), at local, cross-border and international levels.

In addition, Koenraad was an assistant Professor at the University of Brussels (VUB) in Financial Law. He holds a law degree from the University of Brussels (VUB) and an MBA from EHSAL Brussels.